小中大
1. Obstacles and pitfalls in the PEGylation of therapeutic proteins
V. Gaberc-Porekar, I. Zore, B. Podobnik, V. Menart.
Curr. Opin. Drug Discov. Dev., 2008,11:242–250.
cuturl('http://www.biomedcentral.com/render/render.asp?arx_id=cd-877276&type=pdf&access=denied')
2. PEGylation: an approach for drug delivery. A review.
Jain A, Jain SK.
Crit Rev Ther Drug Carrier Syst. 2008;25(5):403-47. Review.
cuturl('http://dl.begellhouse.com/journals/3667c4ae6e8fd136'),5c6300a248a5f5e1,171be91337221ac9.html
3. The impact of PEGylation on biological therapies
Veronese FM, Mero A.
BioDrugs. 2008;22(5):315-29. Review.
cuturl('http://chinesesites.library.ingentaconnect.com/content/adis/bio/2008/00000022/00000005/art00004#avail')
4. Emerging PEGylated drugs
Kang JS, Deluca PP, Lee KC.
Expert Opin Emerg Drugs. 2009 May 20.
cuturl('http://www.informapharmascience.com/doi/abs/10.1517/14728210902907847?cookieSet=1&journalCode=emd')
5. PEG-modified ***aceuticals
Bailon P, Won CY.
Expert Opin Drug Deliv. 2009 Jan;6(1):1-16. Review.
cuturl('http://www.informapharmascience.com/doi/abs/10.1517/17425240802650568')
6. Advances in PEGylation of important biotech molecules: delivery aspects
Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ.
Expert Opin Drug Deliv. 2008 Apr;5(4):371-83. Review.
cuturl('http://www.informapharmascience.com/doi/abs/10.1517/17425247.5.4.371')